Shahab M, Waqas M, Fahira A, Sharma B, Zhang H, Zheng G
Mol Divers. 2025; .
PMID: 39899126
DOI: 10.1007/s11030-025-11119-4.
El Hassab M, Eldehna W, Hassan G, Abou-Seri S
BMC Chem. 2025; 19(1):30.
PMID: 39893479
PMC: 11786381.
DOI: 10.1186/s13065-025-01389-2.
Chernyshova I, Vasileva I, Moor N, Ivanisenko N, Kutuzov M, Abramova T
Int J Mol Sci. 2024; 25(23).
PMID: 39684238
PMC: 11640836.
DOI: 10.3390/ijms252312526.
Koshkina D, Maluchenko N, Korovina A, Lobanova A, Feofanov A, Studitsky V
Biomolecules. 2024; 14(11).
PMID: 39595575
PMC: 11591765.
DOI: 10.3390/biom14111398.
Drew Y, Zenke F, Curtin N
Nat Rev Drug Discov. 2024; 24(1):19-39.
PMID: 39533099
DOI: 10.1038/s41573-024-01060-w.
Synthesis and In Silico Evaluation of Piperazine-Substituted 2,3-Dichloro-5,8-dihydroxy-1,4-naphthoquinone Derivatives as Potential PARP-1 Inhibitors.
Nemetova U, Si Yah P, Boran T, Bi Lgi C, Ozyurek M, Sahi Nler Ayla S
ACS Omega. 2024; 9(38):39733-39742.
PMID: 39346823
PMC: 11425603.
DOI: 10.1021/acsomega.4c04915.
Molecular mechanism of PARP inhibitor resistance.
Huang Y, Chen S, Yao N, Lin S, Zhang J, Xu C
Oncoscience. 2024; 11:69-91.
PMID: 39318358
PMC: 11420906.
DOI: 10.18632/oncoscience.610.
Combining Data-Driven and Structure-Based Approaches in Designing Dual PARP1-BRD4 Inhibitors for Breast Cancer Treatment.
Feng B, Yu H, Dong X, Diaz-Holguin A, Antolin A, Hu H
J Chem Inf Model. 2024; 64(19):7725-7742.
PMID: 39292752
PMC: 11480993.
DOI: 10.1021/acs.jcim.4c01421.
Design and synthesis of novel chloropyridazine hybrids as promising anticancer agents acting by apoptosis induction and PARP-1 inhibition through a molecular hybridization strategy.
Abdelrahman N, Al-Karmalawy A, Jaballah M, Yahya G, Sharaky M, Abouzid K
RSC Med Chem. 2024; 15(3):981-997.
PMID: 38516606
PMC: 10953493.
DOI: 10.1039/d3md00751k.
Novel modifications of PARP inhibitor veliparib increase PARP1 binding to DNA breaks.
Velagapudi U, Rouleau-Turcotte E, Billur R, Shao X, Patil M, Black B
Biochem J. 2024; 481(6):437-460.
PMID: 38372302
PMC: 11070930.
DOI: 10.1042/BCJ20230406.
Interaction between lncRNAs and RNA-binding proteins (RBPs) influences DNA damage response in cancer chemoresistance.
Alemi F, Poornajaf Y, Hosseini F, Vahedian V, Gharekhani M, Shoorei H
Mol Biol Rep. 2024; 51(1):308.
PMID: 38366290
DOI: 10.1007/s11033-024-09288-w.
Synthetically accessible de novo design using reaction vectors: Application to PARP1 inhibitors.
Ghiandoni G, Flanagan S, Bodkin M, Nizi M, Galera-Prat A, Brai A
Mol Inform. 2024; 43(4):e202300183.
PMID: 38258328
PMC: 11475289.
DOI: 10.1002/minf.202300183.
Synthetic Approaches to Piperazine-Containing Drugs Approved by FDA in the Period of 2011-2023.
Romanelli M, Braconi L, Gabellini A, Manetti D, Marotta G, Teodori E
Molecules. 2024; 29(1).
PMID: 38202651
PMC: 10780301.
DOI: 10.3390/molecules29010068.
Targeting the DNA Damage Response for Cancer Therapy.
Wang R, Sun Y, Li C, Xue Y, Ba X
Int J Mol Sci. 2023; 24(21).
PMID: 37958890
PMC: 10648182.
DOI: 10.3390/ijms242115907.
In Silico Mixed Ligand/Structure-Based Design of New CDK-1/PARP-1 Dual Inhibitors as Anti-Breast Cancer Agents.
Bono A, La Monica G, Alamia F, Mingoia F, Gentile C, Peri D
Int J Mol Sci. 2023; 24(18).
PMID: 37762072
PMC: 10531453.
DOI: 10.3390/ijms241813769.
Hypoxia-activated prodrugs of phenolic olaparib analogues for tumour-selective chemosensitisation.
Wong W, OBrien-Gortner S, Anderson R, Wilson W, Hay M, Dickson B
RSC Med Chem. 2023; 14(7):1309-1330.
PMID: 37484567
PMC: 10357951.
DOI: 10.1039/d3md00117b.
Preclinical Efficacy of a PARP-1 Targeted Auger-Emitting Radionuclide in Prostate Cancer.
Sreekumar S, Zhou D, Mpoy C, Schenk E, Scott J, Arbeit J
Int J Mol Sci. 2023; 24(4).
PMID: 36834491
PMC: 9967758.
DOI: 10.3390/ijms24043083.
PARP1pred: a web server for screening the bioactivity of inhibitors against DNA repair enzyme PARP-1.
Lerksuthirat T, Chitphuk S, Stitchantrakul W, Dejsuphong D, Malik A, Nantasenamat C
EXCLI J. 2023; 22:84-107.
PMID: 36814851
PMC: 9939779.
DOI: 10.17179/excli2022-5602.
Targeting the DNA damage response for cancer therapy.
Curtin N
Biochem Soc Trans. 2023; 51(1):207-221.
PMID: 36606678
PMC: 9988002.
DOI: 10.1042/BST20220681.
[1,2,4]Triazolo[3,4-]benzothiazole Scaffold as Versatile Nicotinamide Mimic Allowing Nanomolar Inhibition of Different PARP Enzymes.
Murthy S, Nizi M, Maksimainen M, Massari S, Alaviuhkola J, Lippok B
J Med Chem. 2023; 66(2):1301-1320.
PMID: 36598465
PMC: 9884089.
DOI: 10.1021/acs.jmedchem.2c01460.
